Better Cancer Immunotherapy Drugs Through X-Ray Crystallography
May 30, 2017—(BRONX, NY)—Immunotherapy drugs to combat cancer have stimulated tremendous excitement among patients and physicians alike. They debuted in 2011, when the U.S. Food and Drug Administration approved ipilimumab (Yervoy) to treat metastatic melanoma, a usually fatal disease. Since then, other immunotherapies have reached the market, including pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq) and avelumab (Bavencio).
Source: Einstein News - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Immunotherapy | Melanoma | Skin Cancer | Universities & Medical Training | Yervoy